About irinotecan
Antineoplastic topoisomerase I inhibitor
Used for
- Treatment of advanced colorectal cancer, usually with other medicines.
Usual adult dose
Often 180 mg/m² intravenously over 90 minutes every two weeks with other chemotherapy; regimens vary.
Common side effects
- Diarrhea, which can be severe or life-threatening
- Nausea and vomiting
- Low blood-cell counts and increased infection risk
- Hair loss and fatigue
Important warnings
- Severe diarrhea may begin during or after treatment and needs prompt medical care.
- Low white-cell counts can cause serious infections; blood tests are required.
- Treatment requires specialist supervision and dosing based on body surface area and blood tests.
- Avoid live vaccines during treatment; severe reactions are possible.
Pregnancy
Can harm an unborn baby. Pregnancy should be avoided during treatment and for at least six months afterward.
Breastfeeding
Breastfeeding is not recommended during treatment and for one month after the last dose.
Interactions
- Strong CYP3A4 inhibitors or inducers can alter irinotecan levels.
- St John’s wort can reduce irinotecan levels and should be avoided.
- Other medicines that suppress bone marrow may increase infection risk.
- Live vaccines may cause serious infection during treatment.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.